Xu Su, Hui Yu, Qingqiang Lei, Xuerui Chen, Yanli Tong, Zhongyang Zhang, Wenyong Yang, Yuanbiao Guo, Liangbin Lin
{"title":"Systemic lupus erythematosus: pathogenesis and targeted therapy.","authors":"Xu Su, Hui Yu, Qingqiang Lei, Xuerui Chen, Yanli Tong, Zhongyang Zhang, Wenyong Yang, Yuanbiao Guo, Liangbin Lin","doi":"10.1186/s43556-024-00217-8","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress and status of traditional and emerging treatment strategies for SLE. Traditional treatment strategies for SLE have mainly employed non-specific approaches, including cytotoxic and immunosuppressive drugs, antimalarials, glucocorticoids, and NSAIDs. These strategies are effective in mitigating the effects of the disease, but they are not a complete cure and are often accompanied by adverse reactions. Emerging targeted therapeutic drugs, on the other hand, aim to control and treat SLE by targeting B and T cells, inhibiting their activation and function, as well as the abnormal activation of the immune system. A deeper understanding of the pathogenesis of SLE and the exploration of new targeted treatment strategies are essential to advance the treatment of this complex autoimmune disease.</p>","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"54"},"PeriodicalIF":6.3000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522254/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43556-024-00217-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress and status of traditional and emerging treatment strategies for SLE. Traditional treatment strategies for SLE have mainly employed non-specific approaches, including cytotoxic and immunosuppressive drugs, antimalarials, glucocorticoids, and NSAIDs. These strategies are effective in mitigating the effects of the disease, but they are not a complete cure and are often accompanied by adverse reactions. Emerging targeted therapeutic drugs, on the other hand, aim to control and treat SLE by targeting B and T cells, inhibiting their activation and function, as well as the abnormal activation of the immune system. A deeper understanding of the pathogenesis of SLE and the exploration of new targeted treatment strategies are essential to advance the treatment of this complex autoimmune disease.
系统性红斑狼疮(SLE)是一种多发性自身免疫性疾病,其特点是免疫反应失调和自身抗体产生,影响多个器官,临床表现和疾病严重程度各不相同。系统性红斑狼疮的发病过程错综复杂,包括免疫系统失调、免疫耐受崩溃、遗传易感性以及各种环境因素的诱发。本综述全面论述了系统性红斑狼疮的发病机制和治疗策略,并重点介绍了系统性红斑狼疮传统和新兴治疗策略的进展和现状。系统性红斑狼疮的传统治疗策略主要采用非特异性方法,包括细胞毒和免疫抑制剂、抗疟药、糖皮质激素和非甾体抗炎药。这些策略能有效减轻疾病的影响,但并不能彻底治愈疾病,而且往往伴有不良反应。另一方面,新出现的靶向治疗药物旨在通过靶向 B 细胞和 T 细胞,抑制它们的活化和功能,以及免疫系统的异常活化,从而控制和治疗系统性红斑狼疮。深入了解系统性红斑狼疮的发病机理,探索新的靶向治疗策略,对于推进这种复杂的自身免疫性疾病的治疗至关重要。